This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Delivered as Hybrid Event from 15-17 November 2021
Live In-Person Conference Delivered 15-17 NovemberSheraton Airport Brussels, Belgium

Andy Lewis, Ph.D.
Vice President of Pharmaceutical Sciences at Quotient Sciences


Andy Lewis, BPharm MAPS PhD is VP Pharmaceutical Sciences at Quotient Sciences where he leads a team of 120 scientists working on formulation development, clinical manufacturing and pharmaceutical analysis for clients’ drug product programs. Prior to this he was Director Novel Drug Delivery Technologies at Ipsen, where he had global responsibility for product development utilizing novel formulation technologies or drug delivery devices. He has also helped set up and grow two venture capital funded start ups, RegenTec and Critical Pharmaceuticals, where he led the development and commercialization of novel technologies in the fields of tissue engineering and drug delivery, taking them from concept into clinical development. He has a particular interest in overcoming drug delivery challenges, including sustained release and transmucosal delivery of proteins and peptides, and he has filed a number of patents in the field. He is a member of the Academy of Pharmaceutical Scientists of Great Britain, and has served on the board of directors of the Controlled Release Society (CRS) as Director-at-Large and most recently as Secretary.

Agenda Sessions

  • Accelerating Peptide Development: Strategies to Optimize the Formulation and Delivery of Peptide Therapeutics